Dysport for Forehead Scarring After Nasal Reconstruction

This study is looking at whether injections of Dysport (Abobotulinumtoxin-A), a common "Botox" type of medication, can improve the appearance and your satisfaction with a forehead scar. This scar happens after a paramedian forehead flap (PMFF) surgery, which is used to repair nasal defects from skin cancer removal (like basal cell carcinoma, squamous cell carcinoma, or melanoma). You would be randomly assigned to one of two groups: one receiving Dysport injections or one receiving saline (saltwater) injections at the forehead incision site during surgery. Researchers will measure how the scar looks and your satisfaction at various times up to one year after surgery. The study aims to enroll 50 adults aged 18 and older who need this type of nasal reconstruction.

Study design
This is a randomized study, meaning participants are randomly assigned to one of two groups. It plans to enroll 50 participants.
What's involved
You would receive an injection during surgery and have your scar assessed and satisfaction measured at 1 week, 1 month, 3 months, 6 months, and 1 year post-operatively.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for one year after their surgery to assess scar appearance and satisfaction.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07720726

Impact of Dysport on PMFF Donor Scar

Not Yet Recruiting
PHASE4Ages 18+InterventionalTreatment
Vanderbilt University Medical Center
~50 participants
Updated 2026-07-22 on ClinicalTrials.gov
What's tested:Abobotulinumtoxin-AControl- Saline injection

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Patient Observer Scar Assessment Scale (POSAS)
Measured over POSAS scale will be administered at 1 week, 1 month, 3 months, 6 months, and 1 year post-operatively
+3 more outcomes measured
Skin Cancer Excision Site
Basal Cell Carcinoma
Squamous Cell Carcinoma
Melanoma
1 sites across 1 states
Tennessee1
  • Shiayin F Yang, MD · PRINCIPAL_INVESTIGATOR · Vanderbilt University Medical Center

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults at least 18 years of age with a post-mohs micrographic surgery nasal defect requiring PMFF reconstruction in the operating room or clinic at our institution
No other facial plastic surgery procedure or skin cancer reconstruction performed simultaneously

Exclusion

Documented allergy to Abobotulinumtoxin-A
Previous hypersensitivity to Abobotulinumtoxin-A
Hypersensitivity to any botulinum toxin product or excipients
Previous adverse reaction to any botulinum toxin product or excipients
Allergy to cow's milk protein
Infection at proposed injection site
Previous scar or surgery at proposed injection site
Inability to follow-up in clinic
Inability to provide informed consent
Patient currently on aminoglycoside or other agent interfering with neuromuscular transmission
Patient on anticholinergic medication
Pregnancy
  • Patient Observer Scar Assessment Scale (POSAS)POSAS scale will be administered at 1 week, 1 month, 3 months, 6 months, and 1 year post-operatively

    Patient satisfaction with the appearance of the forehead donor site will be assessed at pre-determined time intervals using the Patient Observer Scar Assessment Scale (POSAS). This is a 7 question scale with all questions answered 1-10. Minimum final score value is 7 with maximum being 70. A higher score means a worse outcome.

  • Patient Satisfaction Likert ScalePatient Satisfaction Likert scale will be administered at 1 week, 1 month, 3 months, 6 months, and 1 year post-operatively

    Overall patient satisfaction with post-operative scar appearance will be evaluated with 5 separate Likert Scale questions ranked 1-10 with higher scores demonstrating a worse outcome.

  • Vancouver Scar ScaleAssessed at 1 week, 1 month, 3 months, 6 months, and 1 year post-operatively

    Appearance of Forehead Donor Site will be assessed at determined post-operative intervals by a blinded attending surgeon using the Vancouver Scar Scale (VSS). This scale includes four categories that assess scar characteristics. Final scores have a minimum value of 0 and a maximum value of 13 with a higher score demonstrating a worse outcome.

  • Physician Graded Scar MetricsAssessed at 1 week, 1 month, 3 months, 6 months, and 1 year post-operatively

    Appearance of Forehead Donor Site will be assessed at determined post-operative intervals by a blinded attending surgeon. Scar width (mm) as well as abnormal scar healing will be assessed and documented. Abnormal scar healing categories include none, hypertrophic scar, and keloid scar. No numeric values will be assigned to this scale.